Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05035316
Other study ID # H-21014515
Secondary ID 2021-000862-14
Status Recruiting
Phase Phase 2
First received
Last updated
Start date January 20, 2022
Est. completion date December 1, 2024

Study information

Verified date January 2024
Source Mental Health Services in the Capital Region, Denmark
Contact Lars V Kessing, Prof
Phone +4538647081
Email lars.vedel.kessing@regionh.dk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Despite currently available treatment, a large proportion of patients with bipolar disorder (BD) suffer from affective symptoms, impaired psychosocial and cognitive function. Inflammation seems to be involved in the pathogenesis of BD and preliminary data suggest that low-dose Aspirin may have beneficial effects. The objective of this RCT is to investigate whether add on of low dose aspirin versus placebo add on to standard drug treatment improves mood stabilisation and other critical patient outcomes in patients with BD and whether its principal effects are antimanic, antidepressant or prophylactic against relapse. randomized double-blinded placebo-controlled trial will investigate whether augmentation with low dose Aspirin to standard drug treatment improve mood stabilization.


Description:

BD is increasingly conceived as a multisystem disorder with pathophysiologic abnormalities involving inflammation, oxidative stress imbalance, neurotrophic deficiencies and telomere shortening. Specifically, inflammation has been confirmed to be involved in the pathogenesis of BD. Emerging yet compelling data converge to suggest that aspirin may protect against the onset and deterioration in BD. Nevertheless, a pragmatic large scale RCT is needed to for a conclusive risk-benefit analysis of aspirin and to clarify its therapeutic role at the different clinical stages of BD.The investigators propose to include smartphone-based self-assessment of mood as the primary outcome measure in the RCT. Thus, during the last ten years, the investigators have developed and tested a unique smartphone-based system, the Monsenso system, for monitoring, diagnosing and treating BD. The trial is designed as a two arm, parallel randomized trial with randomisation 1:1 to add on of low dose aspirin (Hjertemagnyl 150 mg/day) versus add-on of placebo to current treatment and with stratification according to age (< 30 years) and gender. The trial is planned and will be conducted in concordance with the CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. Patients will be included from The Copenhagen Affective Disorder Clinic, which is a mood disorder clinic providing treatment service for patients with newly diagnosed/first episode BD from the entire Capital Region of Denmark covering a catchment area of 1.6 million people and all psychiatric centres in the region. The Clinic receives more than 300 patients with newly diagnosed BD each year. we wish to test the following hypotheses: Adding LDA versus placebo to standard drug treatment for BD will reduce 1) mood instability (MI), and 2) other critical outcomes such as activity instability and severity of depression. Finally, we hypothesize that the reduction in MI is higher in patients with systemic inflammation at baseline indexed with the biomarkers high-sensitivity C-reactive protein (hsCRP), IL-6, and soluble urokinase plasminogen activator receptor (suPAR).


Recruitment information / eligibility

Status Recruiting
Enrollment 250
Est. completion date December 1, 2024
Est. primary completion date December 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Bipolar disorder (type 1 or 2), with diagnoses confirmed by SCAN interview. - Age 18-65 years - Habile (i.e. able to give informed consent) Exclusion Criteria: - Chronic kidney disease with GFR 0-10 ml/min - Severe cardiac insufficiency (NYHA IIIb-IV) - History of gastric ulcers, gastro-intestinal bleeding or other pathological bleeding tendency (thrombocytopenia, hemophilia, vitamin K deficiency) - Asthma or other allergic symptoms developed after intake of salicylates, paracetamol or other NSAID or any of the excipients - Patients already on aspirin or other NSAID, anticoagulants or SSRIs. - For fertile females: - Reluctance to use effective contraception during enrollment, including a safety period of one week following last medication day/trial completion - Pregnancy; pregnancy ruled out by HCG test before enrollment - Breastfeeding - Planned major surgery during trial period. If a subject has scheduled major surgery (i.e. with bleeding risk), enrollment will be postponed until this is completed

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
acetylsalicylic acid
Oral tablet: acetylsalicylic acid,150 mg, 1 tablet/day
Calcium
Oral tablet: calcium, 1 tablet/day

Locations

Country Name City State
Denmark Psychiatric Center Copenhagen Copenhagen

Sponsors (1)

Lead Sponsor Collaborator
Lars Vedel Kessing

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Other Automatically smartphone-generated data Level of physical activity measured by an accelerometer, social activity expressed as numbers of outgoing and incoming calls and text messages/24h, and time spent on the smartphone 6 months
Other Cognition Cognition is assessed at baseline and at 6 months follow-up according to the clinician-administered Screen for Cognitive Impairment in Psychiatry tool. Changes between baseline score and score at 6 months-follow-up
Other Manic symptoms Manic symptoms assessed by the Young Mania Rating Scale (min. value = 0; max. value = 60, with higher values reflecting more manic symptoms) Changes between baseline levels, 3 and 6 months
Other Self-rated sleep quality Self-rated sleep quality assessed by completion of the Pittsburgh Sleep Quality Index. This questionnaire does not use a predefined scale. Changes between baseline levels, 3 and 6 months
Other General functioning General functioning assessed by the Functional Assessment Short Test, a 24-item interviewer-administered interview concerning autonomy, occupational functioning, cognitive functioning, financial issues, interpersonal relationships and leisure time (min. value = 0; max. value = 72, with higher values reflecting poorer function) Changes between baseline levels, 3 and 6 months
Other Self-rated perceived stress level Self-rated stress level assessed by completion of Cohen's Perceived Stress Scale, a 10-item questionnaire. (Min. value = 0; max. value = 40, with higher values reflecting increased stress level Changes between baseline levels, 3 and 6 months
Other Self-rated quality of life Self-rated quality of life assessed by completion of the WHO Quality of Life-BREF questionnaire. (Min. value = 9; max. value = 45, with higher values reflecting better quality of life) Changes between baseline levels, 3 and 6 months
Other Self-reported hours of sleep Daily self-reported hours of sleep collected via the Monsenso-App. 6 months
Other Hair cortisol Exploratory outcome: systemic cortisol levels measured expressed by hair cortisol Changes between baseline levels, 3 and 6 months follow-up
Other Dysbiosis and short-chain fatty acid levels As an exploratory outcome, stool samples will be analyzed to investigate the effects of LDA on dysbiosis and short-chain fatty acid levels Difference between the two treatment arms at 6 months follow-up
Other Blood-based biomarkers of inflammation and oxidative stress As an exploratory outcome, we plan to measure the following blood-based biomarkers: hsCRP, cytokine profiling using mesoscale technology and soluble urokinase plasminogen activator receptor (suPAR) as markers of different aspects of inflammation; malondialdehyde, a marker of lipid peroxidation and oxidative stress; brain-derived neurotrophic factor Changes between baseline and 6 months follow-up
Primary Daily self-reported mood instability Daily self-reported mood instability collected via the Monsenso system 6 months (12 months for a subgroup of participants)
Secondary Depressive symptoms Depressive symptoms assessed by the Hamilton Depression Rating Scale-6 items (min. value = 0; max. value = 22, with higher values reflecting more depressive symptoms) Changes between baseline score and score at 6 months-follow-up
Secondary Daily self-reported activity instability Daily self-reported activity instability collected via the Monsenso App Changes between baseline score and score at 6 months-follow-up
See also
  Status Clinical Trial Phase
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT02855762 - Targeting the Microbiome to Improve Clinical Outcomes in Bipolar Disorder N/A
Recruiting NCT05915013 - Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response Phase 1
Recruiting NCT05206747 - Ottawa Sunglasses at Night for Mania Study N/A
Completed NCT02513654 - Pharmacokinetics, Safety and Tolerability of Repeat Dosing Lamotrigine in Healthy Chinese Subjects Phase 1
Recruiting NCT06313918 - Exercise Therapy in Mental Disorders-study N/A
Completed NCT02304432 - Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine Early Phase 1
Recruiting NCT06197048 - Effect of Nutritional Counseling on Anthropometry and Biomarkers in Patients Diagnosed With Schizophrenia/Psychosis or Bipolar Affective Disorder N/A
Completed NCT03497663 - VIA Family - Family Based Early Intervention Versus Treatment as Usual N/A
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Completed NCT02212041 - Electronic Cigarettes in Smokers With Mental Illness N/A
Recruiting NCT05030272 - Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings N/A
Recruiting NCT04298450 - ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention N/A
Active, not recruiting NCT03641300 - Efficacy of Convulsive Therapies for Bipolar Depression N/A
Not yet recruiting NCT04432116 - Time and Virtual Reality in Schizophrenia and Bipolar Disorder N/A
Terminated NCT02909504 - Gao NARASD Lithium Study Phase 4
Terminated NCT02893371 - Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
Completed NCT02970721 - Use of Psychotropic Medications Among Pregnant Women With Bipolar Disorder
Recruiting NCT03088657 - Design and Methods of the Mood Disorder Cohort Research Consortium (MDCRC) Study
Recruiting NCT02481245 - BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study Phase 2